title: HULC and H19 Played Different Roles in Overall and Disease-Free Survival from Hepatocellular Carcinoma after Curative Hepatectomy: A Preliminary Analysis from Gene Expression Omnibus.
abstract: OBJECTIVE
  This study aimed to evaluate the relationships between long noncoding RNAs (lncRNAs) in tumor tissues and hepatocellular carcinoma (HCC) aggressiveness and survival.
  
  
  METHODS
  We correlated the lncRNAs in tumor tissues with HCC survival and clinicopathological features based on Gene Expression Omnibus expression profile GSE36376.
  
  
  RESULTS
  Eight lncRNAs and 240 HCC patients were included. Cox regression analysis indicated that HULC was a positive factor for HCC overall survival (HR = 0.885, 95% CI = 0.797-0.983, and P = 0.023) and disease-free survival time (HR = 0.913, 95% CI = 0.835-0.998, and P = 0.045). H19 and UCA1 were both demonstrated to be risk factors of HCC disease-free survival in multivariate Cox model (HR = 1.071, 95% CI = 1.01-1.137, and P = 0.022 and HR = 2.4, 95% CI = 1.092-5.273, and P = 0.029, resp.). But Kaplan-Meier method showed no significant association between UCA1 and HCC disease-free survival (log rank P = 0.616). Logistic regression demonstrated that H19 was overexpressed in HBV-infected patients (OR = 1.14, 95% CI = 1.008-1.29, and P = 0.037). HULC had a significant association with vascular invasion (OR = 0.648, 95% CI = 0.523-0.803, and P < 0.001). H19 and MEG3 were both considered to be risk factors for high AFP level (OR = 1.45, 95% CI = 1.277-1.646, and P < 0.001 and OR = 1.613, 95% CI = 1.1-2.365, and P = 0.014, resp.).
  
  
  CONCLUSIONS
  Contributing to decreased susceptibility to vascular invasion, upregulation of HULC in tumor tissues was positively associated with HCC survival. In contrast, H19 overexpression might be risk factor for HCC aggressiveness and poor outcomes.
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
authors.forename: Zongguo
authors.initials: Z
authors.lastname: Yang
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
authors.forename: Yunfei
authors.initials: Y
authors.lastname: Lu
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
authors.forename: Qingnian
authors.initials: Q
authors.lastname: Xu
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
authors.forename: Bozong
authors.initials: B
authors.lastname: Tang
authors.affiliation: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea.
authors.forename: Cheol-Keun
authors.initials: CK
authors.lastname: Park
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
authors.forename: Xiaorong
authors.initials: X
authors.lastname: Chen
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D062085:RNA, Long Noncoding / Q000235:genetics*; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C094335:H19 long non-coding RNA; C574685:HULC long non-coding RNA, human; D062085:RNA, Long Noncoding; C515159:UCA1 RNA, human